The administrative head office is located in the National University Hospital, Singapore.

• Our group is led by a Joint Management Committee (JMC), comprising of the Directors of each member institution and a Chairman elected on an annual rotating basis.
• An audit committee audits our clinical trials conducted at the participating member institutions on a regular basis.
• We have established comprehensive Standard Operating Procedures (SOPs) to ensure smooth operations within the group.
• Four business meetings are conducted annually.
• Our group keeps in close contact and follows discussions closely through monthly teleconferences.

The need for high quality and well coordinated clinical trial groups in Asia-Pacific has provided many opportunities for the CTRG in clinical trials and translational research, having established itself as a leader in this region.

The institutions forming the CTRG collectively bring extensive experience in oncology drug development. Investigators from the various CTRG institutions actively discuss and design in-house research studies. We are recognised by the United States National Cancer Institute (NCI)through the formation of an agreement for the conduct of clinical trials, which allows the NCI and CTRG to collaborate and test promising new drugs in Asian cancers at a level which will allow the studies to support United States Food and Drug Administration (FDA) registration of the new drugs.

Besides working with the NCI, we have collaborated with many multinational pharmaceutical and biotechnology companies, as well as research institutions, in oncology clinical trials for cancers of the head and neck, breast, lung, stomach, colon, liver, pancreas and prostate.

These project collaborations have enabled cancer patients in Asia-Pacific to benefit greatly, as previously, these therapies took an average of 10 years to be available on the market, if clinical research was not conducted.

We position ourselves as a major centre for early phase drug development in clinical trials with more sophisticated endpoints, and with expertise in genomics and proteomics research. With the speed of technological advancement in the last decade, it is important to incorporate sophisticated technology in the development of drugs. We have also enhanced our capability to assay anticancer drugs at greater sensitivity and specificity, including metabolite analysis.

We are, undoubtedly, in an exciting phase of development and our efforts are being recognised increasingly by the international academic community and industry. We continue to be able to bring together key opinion leaders in Asia Pacific, attract drug companies to conduct clinical trials, and have also managed to gain recognition through publications in high impact journals